Modifiers of cftr-directed therapy

A method of treating cystic fibrosis (CF) lung disease in a CF patient with a CFTR-directed therapy, the method comprising steps of:

• determining an activity level of SLC26A9 in a sample obtained from said patient by determining a genotype of a single nucleotide polymorphism (SNP) indicative of the activity level of SLC26A9, wherein the SNP is rs7512462 or rs2869027;
• selecting said patient for treatment with said CFTR-directed therapy if the rs7512462 genotype is determined to be CC or TC, and/or if the rs2869027 genotype is determined to be GG or GC;
• and
• administering said CFTR-directed therapy to said selected patient,
• wherein the CF patient comprises a gating mutation in CFTR, and
• wherein the CFTR-direct therapy comprises a CFTR activator, a CFTR potentiator, a CFTR corrector, or any combination thereof.

A method of treating cystic fibrosis (CF) lung disease in a CF patient with a CFTR-directed therapy, the method comprising steps of:

• determining an activity level of SLC26A9 in a sample obtained from said patient by determining a genotype of a single nucleotide polymorphism (SNP) indicative of the activity level of SLC26A9, wherein the SNP is rs7512462 or rs2869027;
• selecting said patient for treatment with said CFTR-directed therapy if the rs7512462 genotype is determined to be CC or TC, and/or if the rs2869027 genotype is determined to be GG or GC;
• and
• administering said CFTR-directed therapy to said selected patient,
• wherein the CF patient comprises a Phe508del mutation in CFTR, and
• wherein the CFTR-direct therapy comprises a CFTR activator, a CFTR potentiator, a CFTR corrector, or any combination thereof.